Search | VHL Search Portal

1.

Discovering dominant tumor immune archetypes in a pan-cancer census.

Combes, Alexis J; Samad, Bushra; Tsui, Jessica; Chew, Nayvin W; Yan, Peter; Reeder, Gabriella C; Kushnoor, Divyashree; Shen, Alan; Davidson, Brittany; Barczak, Andrea J; Adkisson, Michael; Edwards, Austin; Naser, Mohammad; Barry, Kevin C; Courau, Tristan; Hammoudi, Taymour; Argüello, Rafael J; Rao, Arjun Arkal; Olshen, Adam B; Cai, Cathy; Zhan, Jenny; Davis, Katelyn C; Kelley, Robin K; Chapman, Jocelyn S; Atreya, Chloe E; Patel, Amar; Daud, Adil I; Ha, Patrick; Diaz, Aaron A; Kratz, Johannes R; Collisson, Eric A; Fragiadakis, Gabriela K; Erle, David J; Boissonnas, Alexandre; Asthana, Saurabh; Chan, Vincent; Krummel, Matthew F.

Cell ; 185(1): 184-203.e19, 2022 01 06.

Article in English | MEDLINE | ID: mdl-34963056

2.

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4⁺ T Cell Immunity.

Binnewies, Mikhail; Mujal, Adriana M; Pollack, Joshua L; Combes, Alexis J; Hardison, Emily A; Barry, Kevin C; Tsui, Jessica; Ruhland, Megan K; Kersten, Kelly; Abushawish, Marwan A; Spasic, Marko; Giurintano, Jonathan P; Chan, Vincent; Daud, Adil I; Ha, Patrick; Ye, Chun J; Roberts, Edward W; Krummel, Matthew F.

Cell ; 177(3): 556-571.e16, 2019 04 18.

Article in English | MEDLINE | ID: mdl-30955881

3.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-Î³ and IL-12.

Garris, Christopher S; Arlauckas, Sean P; Kohler, Rainer H; Trefny, Marcel P; Garren, Seth; Piot, Cécile; Engblom, Camilla; Pfirschke, Christina; Siwicki, Marie; Gungabeesoon, Jeremy; Freeman, Gordon J; Warren, Sarah E; Ong, SuFey; Browning, Erica; Twitty, Christopher G; Pierce, Robert H; Le, Mai H; Algazi, Alain P; Daud, Adil I; Pai, Sara I; Zippelius, Alfred; Weissleder, Ralph; Pittet, Mikael J.

Immunity ; 49(6): 1148-1161.e7, 2018 12 18.

Article in English | MEDLINE | ID: mdl-30552023

4.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-Î³ and IL-12.

Garris, Christopher S; Arlauckas, Sean P; Kohler, Rainer H; Trefny, Marcel P; Garren, Seth; Piot, Cécile; Engblom, Camilla; Pfirschke, Christina; Siwicki, Marie; Gungabeesoon, Jeremy; Freeman, Gordon J; Warren, Sarah E; Ong, SuFey; Browning, Erica; Twitty, Christopher G; Pierce, Robert H; Le, Mai H; Algazi, Alain P; Daud, Adil I; Pai, Sara I; Zippelius, Alfred; Weissleder, Ralph; Pittet, Mikael J.

Immunity ; 55(9): 1749, 2022 Sep 13.

Article in English | MEDLINE | ID: mdl-36103861

5.

TCR-sequencing in cancer and autoimmunity: barcodes and beyond.

Pauken, Kristen E; Lagattuta, Kaitlyn A; Lu, Benjamin Y; Lucca, Liliana E; Daud, Adil I; Hafler, David A; Kluger, Harriet M; Raychaudhuri, Soumya; Sharpe, Arlene H.

Trends Immunol ; 43(3): 180-194, 2022 03.

Article in English | MEDLINE | ID: mdl-35090787

6.

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.

Wong, Paul; Wisneski, Andrew D; Tsai, Katy K; Chang, Tammy T; Hirose, Kenzo; Nakakura, Eric K; Daud, Adil I; Maker, Ajay V; Corvera, Carlos U.

World J Surg Oncol ; 22(1): 77, 2024 Mar 11.

Article in English | MEDLINE | ID: mdl-38468341

7.

Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.

Levine, Lauren S; Mahuron, Kelly M; Tsai, Katy K; Wu, Clinton; Mattis, Daiva M; Pauli, Mariela L; Oglesby, Arielle; Lee, James C; Spitzer, Matthew H; Krummel, Matthew F; Algazi, Alain P; Rosenblum, Michael D; Alvarado, Michael; Daud, Adil I.

Ann Surg Oncol ; 27(11): 4122-4130, 2020 Oct.

Article in English | MEDLINE | ID: mdl-32488521

8.

Prognostic Biomarkers for Melanoma Immunotherapy.

Twitty, Christopher G; Huppert, Laura A; Daud, Adil I.

Curr Oncol Rep ; 22(3): 25, 2020 02 11.

Article in English | MEDLINE | ID: mdl-32048065

9.

Immunotherapy for melanoma.

Cuevas, Lauren M; Daud, Adil I.

Semin Cutan Med Surg ; 37(2): 127-131, 2018 Jun.

Article in English | MEDLINE | ID: mdl-30040090

10.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi, Alain P; Tsai, Katy K; Shoushtari, Alexander N; Munhoz, Rodrigo R; Eroglu, Zeynep; Piulats, Josep M; Ott, Patrick A; Johnson, Douglas B; Hwang, Jimmy; Daud, Adil I; Sosman, Jeffrey A; Carvajal, Richard D; Chmielowski, Bartosz; Postow, Michael A; Weber, Jeffrey S; Sullivan, Ryan J.

Cancer ; 122(21): 3344-3353, 2016 Nov 15.

Article in English | MEDLINE | ID: mdl-27533448

11.

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

Posch, Christian; Moslehi, Homayoun; Feeney, Luzviminda; Green, Gary A; Ebaee, Anoosheh; Feichtenschlager, Valentin; Chong, Kim; Peng, Lily; Dimon, Michelle T; Phillips, Thomas; Daud, Adil I; McCalmont, Timothy H; LeBoit, Philip E; Ortiz-Urda, Susana.

Proc Natl Acad Sci U S A ; 110(10): 4015-20, 2013 Mar 05.

Article in English | MEDLINE | ID: mdl-23431193

12.

ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.

Mahuron, Kelly M; Levine, Lauren S; Daud, Adil I.

Ann Surg Oncol ; 27(11): 4131-4132, 2020 Oct.

Article in English | MEDLINE | ID: mdl-32488511

13.

Revisiting RECIST: the case of treatment beyond progression.

Daud, Adil I.

Lancet Oncol ; 19(2): 157-159, 2018 02.

Article in English | MEDLINE | ID: mdl-29361472

14.

Negative but not futile: MAGE-A3 immunotherapeutic for melanoma.

Daud, Adil I.

Lancet Oncol ; 19(7): 852-853, 2018 07.

Article in English | MEDLINE | ID: mdl-29908989

15.

Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma.

Haugh, Alexandra M; Daud, Adil I.

Cancer J ; 30(2): 108-112, 2024.

Article in English | MEDLINE | ID: mdl-38527264

16.

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.

Haugh, Alexandra; Daud, Adil I.

Am J Clin Dermatol ; 25(3): 407-419, 2024 May.

Article in English | MEDLINE | ID: mdl-38329690

17.

Melanocytic Neoplasms, Introduction.

Daud, Adil I.

Semin Cutan Med Surg ; 37(2): 87, 2018 Jun.

Article in English | MEDLINE | ID: mdl-30040084

18.

Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations.

Standiford, Taylor C; Patel, Neil N; Singh, Amritpal; Gochman, Grant; Jamie Wu, Tara; Daud, Adil I; Goldberg, Andrew N.

Int Forum Allergy Rhinol ; 13(12): 2248-2251, 2023 Dec.

Article in English | MEDLINE | ID: mdl-37317899

19.

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

Rasco, Drew W; Medina, Theresa; Corrie, Pippa; Pavlick, Anna C; Middleton, Mark R; Lorigan, Paul; Hebert, Chris; Plummer, Ruth; Larkin, James; Agarwala, Sanjiv S; Daud, Adil I; Qiu, Jiaheng; Bozon, Viviana; Kneissl, Michelle; Barry, Elly; Olszanski, Anthony J.

Cancer Chemother Pharmacol ; 92(1): 15-28, 2023 07.

Article in English | MEDLINE | ID: mdl-37219686

20.

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.

Robert, Caroline; Carlino, Matteo S; McNeil, Catriona; Ribas, Antoni; Grob, Jean-Jacques; Schachter, Jacob; Nyakas, Marta; Kee, Damien; Petrella, Teresa M; Blaustein, Arnold; Lotem, Michal; Arance, Ana; Daud, Adil I; Hamid, Omid; Larkin, James; Anderson, James; Krepler, Clemens; Grebennik, Dmitri; Long, Georgina V.

J Clin Oncol ; 41(24): 3998-4003, 2023 08 20.

Article in English | MEDLINE | ID: mdl-37348035

VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export:

Discovering dominant tumor immune archetypes in a pan-cancer census.

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4⁺ T Cell Immunity.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-Î³ and IL-12.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-Î³ and IL-12.

TCR-sequencing in cancer and autoimmunity: barcodes and beyond.

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.

Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.

Prognostic Biomarkers for Melanoma Immunotherapy.

Immunotherapy for melanoma.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.

Revisiting RECIST: the case of treatment beyond progression.

Negative but not futile: MAGE-A3 immunotherapeutic for melanoma.

Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma.

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.

Melanocytic Neoplasms, Introduction.

Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations.

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.